Table 1 Baseline characteristics for all eligible patients in the REVEAL study
| Â | Treatment Group | Â | |
|---|---|---|---|
| Â | Adalimumab (N = 808) | Placebo (N = 397) | P-value 1 |
Age (yrs), mean ± SD1 | 44.1 ± 13.2 | 45.4 ± 13.4 | 0.1177 |
Sex, n (% female)1 | 266 (32.9) | 141 (35.5) | 0.3996 |
Race, n (%)2 | Â | Â | 0.5432 |
   White | 738 (91.3) | 358 (90.2) |  |
   Black | 27 (3.3) | 20 (5.0) |  |
   Asian | 21 (2.6) | 7 (1.8) |  |
   American Indian/Alaska Native | 3 (0.4) | 1 (0.3) |  |
   Other | 19 (2.4) | 11 (2.8) |  |
Ethnicity, n (%)2 | Â | Â | 0.3434 |
   Not Hispanic or Latino | 754 (93.3) | 364 (91.7) |  |
   Hispanic or Latino | 54 (6.7) | 33 (8.3) |  |
Psoriasis history | Â | Â | Â |
   Duration of psoriasis (yrs), mean ± SD1 | 18.6 ± 12.0 | 18.8 ± 12.0 | 0.7309 |
   Concomitant psoriatic arthritis, (% yes)2 | 222 (27.5) | 113 (28.5) | 0.7326 |
   Prior systemic psoriasis therapy, (% yes)2 | 260 (32.2) | 128 (32.2) | 1.0000 |
Psoriasis baseline assessments | Â | Â | Â |
   Percentage of body surface area affected by psoriasis, mean ± SD2 | 25.8 ± 15.5 | 25.6 ± 14.8 | 0.8796 |
   Psoriasis Area and Severity Index, mean ± SD2 | 19.0 ± 7.1 | 18.8 ± 7.1 | 0.7787 |
Physician's global assessment score, n (% yes) 2 | Â | Â | 1.0000 |
   Moderate2 | 416 (51.5) | 219 (55.2) |  |
   Severe | 341 (42.2) | 155 (39.0) |  |
   Very severe | 51 (6.3) | 23 (5.8) |  |